KMDAKamada Ltd.
Price
+18%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.
We are a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. Our strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of our commercial portfolio, including continued investment in the commercialization and life cycle management of our Proprietary Products.
In the company’s own words · 20-F filed Mar 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Kamada Ltd. (KMDA) reported revenue of $45M in Q4 2025 (quarter ended Dec 31, 2025), up 15% from the same quarter a year earlier. That came with a gross margin of 38%. For the full year FY2025, revenue was $180M (+12% year on year) and net income $20M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #10 of 39 by RyuScore